Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the leading companies in the fast-growing GLP-1 weight loss ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s obesity and diabetes drugs, ahead of global patent expiries in 2026.

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

GreensKeeper Asset Management, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

COPENHAGEN (Reuters) -Newly-elected chairman of Wegovy-maker Novo Nordisk, Lars Rebien Sorensen, said on Friday he plans to enhance the board’s pharmaceutical and over-the-counter experience following ...

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.